Reuters logo
BRIEF-Tetraphase Pharmaceuticals' TP-6076 selected by Carb-X to receive $4 mln in research funding
2017年3月30日 / 晚上8点17分 / 6 个月前

BRIEF-Tetraphase Pharmaceuticals' TP-6076 selected by Carb-X to receive $4 mln in research funding

March 30 (Reuters) - Tetraphase Pharmaceuticals Inc

* Tetraphase Pharmaceuticals’ TP-6076 selected by Carb-X to receive $4 million in research funding

* Tetraphase Pharmaceuticals Inc says in preclinical research, TP-6076 has demonstrated potent activity against MDR bacteria Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below